Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 146)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Etomidate |
Approved |
Phase 3 |
|
33125-97-2 |
667484 |
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylic acid
(+)-Ethyl 1-(a-methylbenzyl)imidazole-5-carboxylate
(+)-Ethyl 1-(a-methylbenzyl)imidazole-5-carboxylic acid
(+)-Ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-Ethyl 1-(α-methylbenzyl)imidazole-5-carboxylic acid
(+)-Etomidate
(+)-Etomidic acid
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylate ethyl ester
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-(+)-1-(a-Methylbenzyl)imidazole-5-carboxylate ethyl ester
(R)-(+)-1-(a-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-(+)-1-(Α-methylbenzyl)imidazole-5-carboxylate ethyl ester
(R)-(+)-1-(Α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylate ethyl ester
|
(R)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylate ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
AMIDATE
D-ETOMIDATE
Ethomidate
ETOMIDATE
Etomidato
Etomidatum
Etomidic acid
Hypnomidate
R 16659
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid
Radenarkon
|
|
2 |
|
Iodine |
Approved, Investigational |
Phase 3 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
3 |
|
Streptozocin |
Approved, Investigational |
Phase 3 |
|
18883-66-4, 66395-18-4 |
29327 |
Synonyms:
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
2-Deoxy-2-((methylnitrosoamino)carbonyl)amino-D-glucose
2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
Estreptozocina
N-D-Glucosyl-(2)-n'
N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
N-D-Glucosyl-(2)-n'-nitrosomethylurea
-nitrosomethylharnstoff
NSC-37917
NSC-85998
Streptozocin
|
Streptozocin teva brand
Streptozocine
Streptozocinium
Streptozocinum
Streptozotocin
Streptozotocine
STZ
Teva brand OF streptozocin
U-9889
Zanosar
|
|
4 |
|
Picropodophyllin |
Approved, Investigational |
Phase 3 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
5 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
6 |
|
Etoposide |
Approved |
Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
7 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
8 |
|
Doxorubicin |
Approved, Investigational |
Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
9 |
|
Cadexomer iodine |
Experimental |
Phase 3 |
|
94820-09-4 |
|
Synonyms:
|
10 |
|
Anesthetics, Intravenous |
|
Phase 3 |
|
|
|
11 |
|
Anesthetics, General |
|
Phase 3 |
|
|
|
12 |
|
Anesthetics |
|
Phase 3 |
|
|
|
13 |
|
Hypnotics and Sedatives |
|
Phase 3 |
|
|
|
14 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
15 |
|
Keratolytic Agents |
|
Phase 3 |
|
|
|
16 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
17 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
18 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
19 |
|
Etoposide phosphate |
|
Phase 3 |
|
|
16760419 |
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
20 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
21 |
|
Liposomal doxorubicin |
|
Phase 3 |
|
|
|
22 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
23 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
24 |
|
Acetic acid |
Approved |
Phase 2 |
|
64-19-7 |
176 |
Synonyms:
Acetasol
Acetate
acetate|ethanoic acid
Acetic acid
Acetic acid glacial
Acetic acid, glacial
Aceticum acidum
Acid glacial, acetic
Acid, acetic
Acid, glacial acetic
Acide acetique
acide acétique
ácido acético
AcOH
CH3CO2H
CH3-COOH
e 260
e260
e-260
Essigsaeure
|
Essigsäure
Ethanoat
Ethanoate
Ethanoic acid
Ethoate
Ethoic acid
Ethylate
Ethylic acid
Glacial acetate
Glacial acetic acid
Glacial, acetic acid
HOAc
INS no. 260
Kyselina octova
MeCO2h
MeCOOH
Methanecarboxylate
Methanecarboxylic acid
Vinegar
Vinegar acid
|
|
25 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
26 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
27 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
28 |
|
Vincristine |
Approved, Investigational |
Phase 2 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-OXOVINCALEUKOBLASTIN
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
22-oxovincaleukoblastine|kyocristine|leurocristine sulfate|NSC-67574|Oncovin®
37231
Cellcristin
Citomid
Farmistin
Indole alkaloid
KYOCRISTINE
LCR
Leucristine
Leurocristine
LEUROCRISTINE SULFATE
LILLY-37231
Marqibo
MARQIBO KIT
NSC-67574
Onco TCS
Oncovin
Oncovine
Onkocristin
PFS, Vincasar
|
Sulfate, vincristine
Tecnocris
VCR
VIN
Vincasar
Vincasar PFS
VINCREX
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
VINCRISTINE
Vincristine sulfate
VINCRISTINE SULFATE PFS
VINCRISTINUM
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
|
|
29 |
|
Lactitol |
Approved, Investigational |
Phase 2 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
30 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
31 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
32 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
33 |
|
Axitinib |
Approved, Investigational |
Phase 2 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
34 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
35 |
|
Mitotane |
Approved |
Phase 2 |
|
53-19-0 |
4211 |
Synonyms:
Bristol myers squibb brand OF mitotane
Bristol-myers squibb brand OF mitotane
CB-313
CB-313|Lysodren®
Chloditan
Chlodithan
Chlodithane
Khloditan
Khlodithan
Lysodren
MITOTAN
MITOTANE
MITOTANO
|
MITOTANUM
Mitotanum [INN-Latin]
Mytotan
NSC-38721
o,p′-DDD
o,p′-dichlorodiphenyl-dichloroethane
O,P'-DDD
O,P-DDD
OPDDD
ortho,Para DDD
ortho,Para-DDD
PIPRINE-DDD, O-
|
|
36 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
37 |
|
Ketoconazole |
Approved, Investigational |
Phase 2 |
|
65277-42-1, 142128-57-2 |
47576 3823 638701 |
Synonyms:
(+-)-cis-1-Acetyl-4-(P-((2-(2,4-dichlorophenyl)-2-(imidazol-1- ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine
(2S,4R)-1-Acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
(2S,4R)-ketoconazole|COR-003|COR003|Recorlev®
1-[4-[4-[[2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL]METHOXY]PHENYL]-1-PIPERAZINYL]ETHANONE
1-ACETYL-4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
ABBR KTC
cis-1-Acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H- imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-ketoconazol
COR003
COR-003
DAKTARIN GOLD
DAKTARIN INTENSIV
DANDRAZOL
DANDRID
EXTINA
Fungarest
Fungoral
J02AB02
Janssen brand OF ketoconazole
KETOCONAZOL
Ketoconazole
|
Ketoconazole janssen brand
KETOCONAZOLUM
Ketoderm
Ketoisdin
KETOPINE
KETOSIDIN
KETOZOLE
LEVOKETOCONAZOLE
Nizoral
NIZORAL A-D
Nizoral®|R-41400
NIZORELLE
NSC 317629
NSC-317629
Orifungal m
Panfungol
Piperazine
R-41400
SID456469
Xolegel
|
|
38 |
|
Metyrapone |
Approved, Investigational |
Phase 2 |
|
54-36-4 |
4174 |
Synonyms:
Alliance brand OF metyrapone
MEO885
Mepyrapone
mepyrapone|Metopirone®
Methapyrapone
Methbipyranone
Methopirapone
Methopyrapone
Methopyrinine
Methopyrone
Metirapona
Metopiron
|
Metopirone
Métopirone
Metroprione
Metyrapon
METYRAPONE
Métyrapone
Metyrapone alliance brand
Metyrapone novartis brand
Metyraponum
Novartis brand OF metyrapone
NSC-25265
|
|
39 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
40 |
|
Hydrocortisone succinate |
Approved |
Phase 2 |
|
2203-97-6 |
3643 |
Synonyms:
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
Cortisol 21-(hydrogen succinate)
Cortisol succinate
HYDROCORTISONE HEMISUCCINATE
|
Hydrocortisone hemisuccinate anhydrous
Hydrocortisone hydrogen succinate
HYDROCORTISONE SUCCINATE
Hydroxycortisone succinate
NSC-7576
|
|
41 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Phase 2 |
|
50-03-3 |
|
Synonyms:
21-O-acetylcortisol
BARQUINOL HC
CHLOROMYCETIN HYDROCORT
COLIFOAM
CORTEF ACETATE
CORTIFOAM
Cortisol 21-acetate
CORTRIL
CORTUCID
DRICORT
EPIFOAM
FRAMYCORT
FUCIDIN H
GENTICIN HC
GENTISONE HC
|
GPPE EAR SUSP
GPPE EYE CRM
GPPE FOAM AERO
HC45 HYDROCORT
HEMSOL-HC
HEPACORT PLUS
HYDROCAL
HYDROCORTISONE 21-ACETATE
HYDROCORTISONE ACETATE
HYDROCORTONE
LANACORT
MICORT-HC
NEO-CORTEF
NSC-741
ORABASE HCA
|
|
42 |
|
Hydrocortisone |
Approved, Vet_approved |
Phase 2 |
|
50-23-7 |
3640 5754 |
Synonyms:
(11ALPHA,14BETA)-11,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11Β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(1S,2R,10S,11S,14S,15S,17S)-14,17-DIHYDROXY-14-(2-HYDROXYACETYL)-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11Β,17α,21-trihydroxy-4-pregnene-3,20-dione
11Β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
ACETASOL HC
ACTICO МИХАИЛRT
Acticort
Acticort®|Efmody®|Plenadren®
Aeroseb HC
Aeroseb-HC
Alacort
Ala-cort
Ala-scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort-HC
ANUGESIC HC
Anusol HC
ANUSOL PLUS HC
ANUSOL SOOTHING RELIEF
Anusol-HC
Aquacort
Aquanil HC
Balneol-HC
Barseb HC
Basan-corti
Beta-HC
b-HC
CaldeCORT spray
CALMURID HC
CANESTEN HC
Cetacort
Chronocort
CIPRO HC
Clear aid
Cleiton
Cobadex
Colocort
Compound F
CORLAN
Cor-oticin
Cortanal
Cor-tar-quin
Cort-dome
Cortef
CORTENEM
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisolonum
Cortisporin
Cortisporin otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
CORTRIL
Cremesone
Cremicort-H
Cutisol
DAKTACORT
DAKTACORT HYDROCORT
Delacort
DERMA CARE HYDROCORT
Dermacort
Derm-aid
DERMASPRAY DEMANG
Dermil
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
ECONACORT
Ef corlin
Efcorbin
Efcortelan
EFCORTELAN P
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EURAX-HC
EURAX-HYDROCORT
Evacort
EXE-CORT
Ficortril
Fiocortril
Flexicort
Foille insetti
Genacort
GERMOLOIDS HC
Glycort
GREGODERM
gyno-Cortisone
HC
|
HC #1
HC #4
HC (HYDROCORTISONE)
HC45
H-Cort
Heb cort
Heb-cort
Hi-cor
Hidalone
hidro-Colisona
Hidrocortisona
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
hydro-Colisona
Hydrocort
HYDROCORT IN CALAMINE OILY
HYDROCORT IN CETOMACROGOL FOR A
HYDROCORT IN WTE SOFT PARAF
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
Hydrocortisone sodium phosphate
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisonum
Hydrocortistab
Hydrocortisyl
HYDROCORTONE
HYDRODERM
HYDRODERM HC
hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone lotion
Idrocortisone
Incortin-H
Incortin-hydrogen
JUNGLE FOR
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
Locoid
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
MILDISON LIPOCREAM
Milliderm
neo-Cort-dome
neo-Cortef
Neosporin-H ear
Nogenic HC
NSC-10483
Nutracort
NYBADEX
Nystaform-HC
Ophthocort
Optef
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
OTOSEPTIL
Otosone-F
OTOSPORIN
Pediotic suspension
Penecort
PERINAL
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Prepcort
Prestwick_265
Prevex HC
Proctocort
PROCTOCREAM HC
Proctofoam
PROCTOFOAM HC
PROCTOSEDYL
Protocort
QUINOCORT
Racet
Rectoid
Reichstein's substance m
Remederm HC
Sanatison
Scalpicin capilar
Schericur
Scheroson F
SENTIAL HC
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Tarcortin
Terra-cortril
TERRA-CORTRIL NYSTATIN
Texacort
Timocort
TIMODINE
Topicort
TOPISONE
Transderma H
Traumaide
TRI-CICATRIN
U-cort
Uniderm
UNIROID
UNIROID HC
Vioform-hydrocortisone
VoSol HC
Vytone
XYLOPROCT
Zenoxone
β-HC
|
|
43 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
44 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
45 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
46 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
47 |
|
(-)-Gossypol |
Investigational |
Phase 2 |
|
303-45-7, 90141-22-3 |
3503 |
Synonyms:
(-)-GOSSYPOL
(+)-Gossypol
(+-)-Gossypol
(+/-)-gossypol
(R)-(-)-Gossypol
(r)-2,2'-bis(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene)
(R)-Gossypol
BL-193
Dipotassium salt, gossypol
Gossypol
Gossypol dipotassium salt
Gossypol from cotton seeds
|
Gossypol r-form
Gossypol sodium salt
Gossypol, (-)-isomer
Gossypol, (+)-isomer
Gossypol, (+-)-isomer
NSC-56817
NSC-624336
Pogosin
R-(-)-gossypol
Racemic-gossypol
Sodium salt, gossypol
Tash 1
|
|
48 |
|
Zuretinol acetate |
Investigational |
Phase 2 |
|
127-47-9, 29584-22-3 |
10245972 |
Synonyms:
(2E,4E,6Z)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl acetic acid
13-cis-Retinyl acetate
9-cis-Retinyl acetate
Acetateall-trans-retinol
Acetic acid, retinyl ester
all-trans-Retinol acetate
all-trans-Retinyl acetate
all-trans-Retinylacetate
all-trans-Vitamin a acetate
Crystalets
Dagravit a forte
Davitan a 650
Dif vitamin a masivo
Myvak
Myvax
O(15)-Acetylretinol
O~15~-acetylretinol
O~15~-acetyl-retinol
RetiNit
Retinol acetate
|
Retinol acetate (JP15)
RETINOL acetATE (see retinoidprojects 1 and 3)
Retinol acetate, (9,13-cis)-isomer
Retinol acetic acid
Retinol, acetate
Retinol, acetate, all-trans- (8ci)
Retinol, acetate, labeled with tritium
Retinyl acetate
trans-Retinyl acetate
trans-Vitamin a acetate
Vitamin a acetate
Vitamin a acetate (tritiated)
Vitamin a alcohol acetate
Vitamin a dispersa
Vitamin a ester
Vitamin a, acetate
Vitamin a1 acetate
Vitamin-a-saar
Zuretinol acetate
Zuretinol acetic acid
|
|
49 |
|
Rivoceranib |
Investigational |
Phase 2 |
|
811803-05-1 |
11315474 |
Synonyms:
APATINIB
apatinib (in China)|YN968D1
Apatinib mesylate
Rivoceranib
|
Rivoceranib mesylate
YN968D1
YN968D1 free base
|
|
50 |
|
Suramin |
Investigational |
Phase 2 |
|
129-46-4, 145-63-1 |
5361 |
Synonyms:
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonate
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonIC ACID
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulphonate
8,8'-[CARBONYLBIS[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulphonic acid
Bayer 205
Belganyl
CI-1003
CI-1003|suramine
Hexasodium salt suramin
Monosodium salt suramin
Moranil
Naganin
Naganol
|
Naphuride
NSC-34936
Salt suramin, hexasodium
Salt suramin, monosodium
Sodium suramin
Sodium, suramin
SURAMIN
Suramin sodium
Suramin, hexasodium salt
Suramin, monosodium salt
Suramine
SVR
|
|
Interventional clinical trials:
(show top 50)
(show all 117)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up |
Completed |
NCT01959711 |
Phase 4 |
|
2 |
Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia |
Unknown status |
NCT02010957 |
Phase 3 |
|
3 |
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence |
Unknown status |
NCT00777244 |
Phase 3 |
MITOTANE |
4 |
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence |
Unknown status |
NCT03723941 |
Phase 3 |
Cisplatin plus Etoposide |
5 |
Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening |
Completed |
NCT00037843 |
Phase 3 |
I-131 Iodocholesterol |
6 |
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation |
Completed |
NCT00997594 |
Phase 2, Phase 3 |
|
7 |
First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment |
Completed |
NCT00094497 |
Phase 3 |
Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane |
8 |
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma |
Completed |
NCT00924989 |
Phase 3 |
OSI-906 |
9 |
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial) |
Recruiting |
NCT03583710 |
Phase 3 |
Cisplatin;Etoposide;Mitotane |
10 |
Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study |
Active, not recruiting |
NCT00304070 |
Phase 3 |
doxorubicin hydrochloride;cisplatin;mitotane;etoposide |
11 |
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma |
Unknown status |
NCT03145285 |
Phase 2 |
Abiraterone Acetate |
12 |
Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy |
Unknown status |
NCT00786110 |
Phase 2 |
Sorafenib;Paclitaxel |
13 |
Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines |
Unknown status |
NCT03257891 |
Phase 2 |
Cabazitaxel |
14 |
Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy |
Completed |
NCT00454103 |
Phase 1, Phase 2 |
123I-Iodometomidate |
15 |
A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease |
Completed |
NCT02468193 |
Phase 2 |
Osilodrostat |
16 |
A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) |
Completed |
NCT00848016 |
Phase 2 |
R-(-)-gossypol acetic acid |
17 |
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma |
Completed |
NCT01833832 |
Phase 2 |
Cisplatin;sodium thiosulfate |
18 |
Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy |
Completed |
NCT00453895 |
Phase 2 |
Sunitinib |
19 |
A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) |
Completed |
NCT00215202 |
Phase 2 |
Iressa (ZD1839) |
20 |
Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma |
Completed |
NCT00324012 |
Phase 2 |
cisplatin, taxotere |
21 |
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection |
Completed |
NCT00001339 |
Phase 2 |
doxorubicin, vincristine, and etoposide with mitotane |
22 |
Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma |
Completed |
NCT01514526 |
Phase 2 |
Dovitinib |
23 |
A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors |
Completed |
NCT00831844 |
Phase 2 |
|
24 |
Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies |
Completed |
NCT00002608 |
Phase 2 |
cisplatin;doxorubicin hydrochloride;tamoxifen citrate |
25 |
A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors |
Completed |
NCT00091182 |
Phase 2 |
oxaliplatin |
26 |
A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors |
Completed |
NCT01262235 |
Phase 1, Phase 2 |
TKM-080301 |
27 |
A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection |
Completed |
NCT00071058 |
Phase 2 |
XR9576 (Tariquidar) |
28 |
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer |
Completed |
NCT01255137 |
Phase 2 |
Axitinib |
29 |
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor |
Recruiting |
NCT05436639 |
Phase 2 |
SPI-62 dose1;SPI-62 dose 2;SPI-62 dose 3;SPI-62 dose 4;Placebo |
30 |
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma |
Recruiting |
NCT04187404 |
Phase 1, Phase 2 |
|
31 |
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma |
Recruiting |
NCT03612232 |
Phase 2 |
Cabozantinib-s-malate |
32 |
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma |
Recruiting |
NCT03127774 |
Phase 2 |
Cisplatin;Sodium thiosulfate |
33 |
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours |
Recruiting |
NCT03746431 |
Phase 1, Phase 2 |
[111In]-FPI-1547 Injection;[225Ac]-FPI-1434 Injection multi-dose;[225Ac]-FPI-1434 Injection single-dose |
34 |
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
Recruiting |
NCT03333616 |
Phase 2 |
Ipilimumab;Nivolumab |
35 |
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors |
Recruiting |
NCT05012397 |
Phase 2 |
RAIN-32 |
36 |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
Recruiting |
NCT02834013 |
Phase 2 |
|
37 |
Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies |
Active, not recruiting |
NCT04785287 |
Phase 1, Phase 2 |
|
38 |
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma |
Active, not recruiting |
NCT02673333 |
Phase 2 |
Pembrolizumab |
39 |
A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma |
Active, not recruiting |
NCT03370718 |
Phase 2 |
Cabozantinib |
40 |
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors |
Active, not recruiting |
NCT02721732 |
Phase 2 |
|
41 |
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors |
Active, not recruiting |
NCT02867592 |
Phase 2 |
Cabozantinib;Cabozantinib S-malate |
42 |
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma |
Not yet recruiting |
NCT05634577 |
Phase 2 |
Mitotane;Pembrolizumab |
43 |
A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. |
Not yet recruiting |
NCT05563467 |
Phase 2 |
Pembrolizumab 25 MG/ML [Keytruda] |
44 |
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma |
Not yet recruiting |
NCT04318730 |
Phase 2 |
Camrelizumab |
45 |
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy |
Not yet recruiting |
NCT05036434 |
Phase 2 |
Pembrolizumab / Lenvatinib |
46 |
Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism |
Terminated |
NCT02001051 |
Phase 2 |
|
47 |
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland |
Terminated |
NCT00003453 |
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
48 |
Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone |
Terminated |
NCT00778817 |
Phase 2 |
mitotane |
49 |
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma |
Terminated |
NCT02720484 |
Phase 2 |
Nivolumab |
50 |
Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II |
Terminated |
NCT00002921 |
Phase 2 |
suramin;therapeutic hydrocortisone |
|